Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 18 |
| List of Tables | 17 | 2 |
| List of Figures | 19 | 1 |
| Introduction | 20 | 1 |
| Global Markets Direct Report Coverage | 20 | 1 |
| Chronic Pain Overview | 21 | 1 |
| Therapeutics Development | 22 | 2 |
| Pipeline Products for Chronic Pain Overview | 22 | 1 |
| Pipeline Products for Chronic Pain Comparative Analysis | 23 | 1 |
| Chronic Pain Therapeutics under Development by Companies | 24 | 7 |
| Chronic Pain Therapeutics under Investigation by Universities/Institutes | 31 | 1 |
| Chronic Pain Pipeline Products Glance | 32 | 4 |
| Late Stage Products | 32 | 1 |
| Clinical Stage Products | 33 | 1 |
| Early Stage Products | 34 | 1 |
| Unknown Stage Products | 35 | 1 |
| Chronic Pain Products under Development by Companies | 36 | 8 |
| Chronic Pain Products under Investigation by Universities/Institutes | 44 | 1 |
| Chronic Pain Companies Involved in Therapeutics Development | 45 | 66 |
| AbbVie Inc | 45 | 1 |
| Acadia Pharmaceuticals Inc. | 46 | 1 |
| Adynxx, Inc. | 47 | 1 |
| Allergan Plc | 48 | 1 |
| Amorsa Therapeutics Inc. | 49 | 1 |
| arGEN-X BV | 50 | 1 |
| Asana BioSciences, LLC | 51 | 1 |
| AskAt Inc. | 52 | 1 |
| Astraea Therapeutics, LLC | 53 | 1 |
| Axsome Therapeutics, Inc. | 54 | 1 |
| BioDelivery Sciences International, Inc. | 55 | 1 |
| Biogen Inc | 56 | 1 |
| Bionomics Limited | 57 | 1 |
| Camurus AB | 58 | 1 |
| Cara Therapeutics, Inc. | 59 | 1 |
| Centrexion Therapeutics Corp | 60 | 1 |
| ChironWells GmbH | 61 | 1 |
| Collegium Pharmaceutical, Inc. | 62 | 1 |
| Crinetics Pharmaceuticals, Inc. | 63 | 1 |
| Cyclenium Pharma, Inc. | 64 | 1 |
| Cytogel Pharma, LLC | 65 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 66 | 1 |
| Daiichi Sankyo Company, Limited | 67 | 1 |
| Dompe Farmaceutici S.p.A. | 68 | 1 |
| Echo Pharmaceuticals B.V. | 69 | 1 |
| Egalet Corporation | 70 | 1 |
| Eli Lilly and Company | 71 | 1 |
| Elite Pharmaceuticals, Inc. | 72 | 1 |
| Glenmark Pharmaceuticals Ltd. | 73 | 1 |
| Grunenthal GmbH | 74 | 1 |
| Heron Therapeutics, Inc. | 75 | 1 |
| INSYS Therapeutics, Inc. | 76 | 1 |
| Johnson &Johnson | 77 | 1 |
| Kareus Therapeutics, SA | 78 | 1 |
| KPI Therapeutics, Inc. | 79 | 1 |
| Kymab Limited | 80 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 81 | 1 |
| Lohocla Research Corporation | 82 | 1 |
| Lpath, Inc. | 83 | 1 |
| MD Biosciences GmbH | 84 | 1 |
| Merck &Co., Inc. | 85 | 1 |
| Moberg Pharma AB | 86 | 1 |
| Mundipharma International Ltd | 87 | 1 |
| Nanomerics Ltd | 88 | 1 |
| Nektar Therapeutics | 89 | 1 |
| Neura Therapeutik, LLC | 90 | 1 |
| Orion Oyj | 91 | 1 |
| Pacira Pharmaceuticals, Inc. | 92 | 1 |
| Pain Therapeutics, Inc. | 93 | 1 |
| PeriphaGen, Inc. | 94 | 1 |
| Pfizer Inc. | 95 | 1 |
| Phosphagenics Limited | 96 | 1 |
| Prismic Pharmaceuticals, Inc. | 97 | 1 |
| Purdue Pharma LP | 98 | 1 |
| Relmada Therapeutics, Inc. | 99 | 1 |
| Ribomic Inc. | 100 | 1 |
| Sea4Us | 101 | 1 |
| Shulov Innovative Science Ltd. | 102 | 1 |
| Synactix Pharmaceuticals, Inc. | 103 | 1 |
| Syntrix Biosystems, Inc. | 104 | 1 |
| Teva Pharmaceutical Industries Ltd. | 105 | 1 |
| Therapix Biosciences Ltd. | 106 | 1 |
| Trevena, Inc. | 107 | 1 |
| Voyager Therapeutics, Inc. | 108 | 1 |
| Yooyoung Pharmaceutical Co., Ltd. | 109 | 1 |
| Zynerba Pharmaceuticals, Inc. | 110 | 1 |
| Chronic Pain Therapeutics Assessment | 111 | 20 |
| Assessment by Monotherapy Products | 111 | 1 |
| Assessment by Combination Products | 112 | 1 |
| Assessment by Target | 113 | 7 |
| Assessment by Mechanism of Action | 120 | 7 |
| Assessment by Route of Administration | 127 | 2 |
| Assessment by Molecule Type | 129 | 2 |
| Drug Profiles | 131 | 183 |
| (celecoxib + tramadol hydrochloride) Drug Profile | 131 | 2 |
| (hydrocodone bitartrate + palmidrol) Drug Profile | 133 | 1 |
| (morphine sulfate + palmidrol) Drug Profile | 134 | 1 |
| (naltrexone hydrochloride + oxycodone hydrochloride) SR Drug Profile | 135 | 1 |
| (oxycodone hydrochloride + palmidrol) Drug Profile | 136 | 1 |
| (palmidrol + pregabalin) Drug Profile | 137 | 1 |
| A-200 Drug Profile | 138 | 1 |
| AGN-XX Drug Profile | 139 | 1 |
| AGN-YY Drug Profile | 140 | 1 |
| AMS-520 Drug Profile | 141 | 1 |
| ASN-008 Drug Profile | 142 | 1 |
| AVLX-144 Drug Profile | 143 | 1 |
| AXS-06 Drug Profile | 144 | 1 |
| AYX-1 Drug Profile | 145 | 2 |
| AYX-2 Drug Profile | 147 | 1 |
| BBI-11008 Drug Profile | 148 | 1 |
| bupivacaine Drug Profile | 149 | 2 |
| bupivacaine hydrochloride Drug Profile | 151 | 2 |
| buprenorphine hydrochloride Drug Profile | 153 | 2 |
| buprenorphine hydrochloride depot Drug Profile | 155 | 1 |
| buprenorphine hydrochloride ER Drug Profile | 156 | 2 |
| buprenorphine hydrochloride long acting Drug Profile | 158 | 1 |
| cebranopadol Drug Profile | 159 | 3 |
| cetirizine hydrochloride + cromolyn sodium Drug Profile | 162 | 1 |
| cetuximab Drug Profile | 163 | 6 |
| CNTX-0290 Drug Profile | 169 | 1 |
| CNV-3000164 Drug Profile | 170 | 1 |
| CNV-3000223 Drug Profile | 171 | 1 |
| CR-4056 Drug Profile | 172 | 1 |
| CR-701 Drug Profile | 173 | 1 |
| CRB-0089 Drug Profile | 174 | 1 |
| Cyt-1010 Drug Profile | 175 | 2 |
| dexmedetomidine hydrochloride Drug Profile | 177 | 2 |
| DF-2593A Drug Profile | 179 | 1 |
| difelikefalin Drug Profile | 180 | 7 |
| dronabinol Drug Profile | 187 | 2 |
| DS-1971 Drug Profile | 189 | 1 |
| DWJ-208 Drug Profile | 190 | 1 |
| ECP-1014 Drug Profile | 191 | 1 |
| Egalet-003 Drug Profile | 192 | 1 |
| fluticasone propionate Drug Profile | 193 | 1 |
| FY-101C Drug Profile | 194 | 1 |
| FY-103B Drug Profile | 195 | 1 |
| GBR-900 Drug Profile | 196 | 1 |
| Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain Drug Profile | 197 | 1 |
| grapiprant Drug Profile | 198 | 2 |
| HPI-201 Drug Profile | 200 | 1 |
| HS-731 Drug Profile | 201 | 1 |
| hydrocodone bitartrate ER Drug Profile | 202 | 3 |
| hydrocodone bitartrate ER Drug Profile | 205 | 1 |
| hydrocodone bitartrate ER Drug Profile | 206 | 1 |
| hydromorphone hydrochloride Drug Profile | 207 | 1 |
| Kindolor Drug Profile | 208 | 1 |
| KY-1017 Drug Profile | 209 | 1 |
| L-779976 Drug Profile | 210 | 1 |
| lacosamide Drug Profile | 211 | 1 |
| LEVI-04 Drug Profile | 212 | 1 |
| levorphanol tartrate ER Drug Profile | 213 | 2 |
| Lpathomab Drug Profile | 215 | 3 |
| MD-354 Drug Profile | 218 | 1 |
| Monoclonal Antibodies for Chronic Pain Drug Profile | 219 | 1 |
| Monoclonal Antibodies to Block Nav1.7 for Chronic Pain Drug Profile | 220 | 1 |
| morphine sulfate ER Drug Profile | 221 | 4 |
| MR-309 Drug Profile | 225 | 2 |
| NET-END Drug Profile | 227 | 1 |
| NKTR-181 Drug Profile | 228 | 3 |
| NL-001 Drug Profile | 231 | 1 |
| NL-002 Drug Profile | 232 | 1 |
| NM-0127 Drug Profile | 233 | 1 |
| Omnitram Drug Profile | 234 | 1 |
| onabotulinumtoxin A Drug Profile | 235 | 5 |
| OSX-300 Drug Profile | 240 | 1 |
| OSX-300 Backups Drug Profile | 241 | 1 |
| oxycodone hydrochloride ER Drug Profile | 242 | 3 |
| oxycodone hydrochloride ER Drug Profile | 245 | 1 |
| oxycodone hydrochloride ER Drug Profile | 246 | 2 |
| oxymorphone hydrochloride Drug Profile | 248 | 1 |
| oxymorphone hydrochloride ER Drug Profile | 249 | 1 |
| PAC-CP Drug Profile | 250 | 1 |
| palmidrol Drug Profile | 251 | 1 |
| Peptide to Block Cav2.2 for CNS Disorders Drug Profile | 252 | 1 |
| Peptides to Inhibit Ion Channel for Chronic Pain Drug Profile | 253 | 1 |
| Peptides to Target TRPV1 for Pain and Itch Drug Profile | 254 | 1 |
| PN-6047 Drug Profile | 255 | 1 |
| PRC-062 Drug Profile | 256 | 1 |
| Prostatic Acid Phosphatase Drug Profile | 257 | 1 |
| PspTx-3 Drug Profile | 258 | 1 |
| raxatrigine hydrochloride Drug Profile | 259 | 3 |
| RBM-005 Drug Profile | 262 | 1 |
| REL-1017 Drug Profile | 263 | 3 |
| SAFit2 Drug Profile | 266 | 1 |
| Small Molecule for Chronic Pain Drug Profile | 267 | 1 |
| Small Molecule for Chronic Pain Drug Profile | 268 | 1 |
| Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain Drug Profile | 269 | 1 |
| Small Molecule to Antagonize GPR-84 for Chronic Pain Drug Profile | 270 | 1 |
| Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders Drug Profile | 271 | 2 |
| Small Molecule to Block Nav1.9 Channel for Pain Drug Profile | 273 | 1 |
| Small Molecule to Inhibit ASK-1 for Chronic Pain Drug Profile | 274 | 1 |
| Small Molecule to Inhibit mPGES-1 for Chronic Pain Drug Profile | 275 | 1 |
| Small Molecules for Chronic Wound Pain Drug Profile | 276 | 1 |
| Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder Drug Profile | 277 | 1 |
| Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain Drug Profile | 278 | 1 |
| Small Molecules to Agonize CB2 for Chronic Pain and Migraine Drug Profile | 279 | 1 |
| Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain Drug Profile | 280 | 1 |
| Small Molecules to Agonize NOP for Pain and Alcohol Addiction Drug Profile | 281 | 1 |
| Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain Drug Profile | 282 | 1 |
| Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain Drug Profile | 283 | 1 |
| Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System Drug Profile | 284 | 1 |
| Small Molecules to Block Cav2.2 Channel for Chronic Pain Drug Profile | 285 | 1 |
| Small Molecules to Block Cav2.2 Channel for Chronic Pain Drug Profile | 286 | 1 |
| Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain Drug Profile | 287 | 1 |
| Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain Drug Profile | 288 | 1 |
| Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System Drug Profile | 289 | 1 |
| Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain Drug Profile | 290 | 1 |
| Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain Drug Profile | 291 | 1 |
| Small Molecules to Inhibit DAAO for Chronic Pain Drug Profile | 292 | 1 |
| Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain Drug Profile | 293 | 1 |
| Small Molecules to Target Opioid Receptors for Chronic Pain Drug Profile | 294 | 1 |
| SYN-003 Drug Profile | 295 | 1 |
| Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain Drug Profile | 296 | 1 |
| tanezumab Drug Profile | 297 | 3 |
| tapentadol hydrochloride IR Drug Profile | 300 | 2 |
| TRV-734 Drug Profile | 302 | 2 |
| U-2902 Drug Profile | 304 | 2 |
| UMB-425 Drug Profile | 306 | 1 |
| Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain Drug Profile | 307 | 1 |
| VM-902A Drug Profile | 308 | 1 |
| VYNAV-01 Drug Profile | 309 | 1 |
| XT-101 Drug Profile | 310 | 1 |
| YYC-301 Drug Profile | 311 | 1 |
| ZEP-3 Drug Profile | 312 | 1 |
| ZYN-001 Drug Profile | 313 | 1 |
| Chronic Pain Dormant Projects | 314 | 9 |
| Chronic Pain Discontinued Products | 323 | 3 |
| Chronic Pain Product Development Milestones | 326 | 8 |
| Featured News &Press Releases | 326 | 1 |
| Aug 25, 2016: Egalet Announces Scientific Presentation on ARYMO ER (morphine sulfate) at PAINWeek 2016 Meeting | 326 | 1 |
| Jul 13, 2016: Cara Therapeutics Data to be Presented at the British Association for Psychopharmacology 2016 Summer Meeting | 327 | 1 |
| Jul 01, 2016: Pain Therapeutics Announces Advisory Committee Meeting for REMOXY Is Not Needed | 327 | 1 |
| Jun 22, 2016: Collegium Announces Positive Topline Results for Hydrocodone DETERx Clinical Study | 327 | 1 |
| Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings | 328 | 1 |
| Jun 07, 2016: Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology | 328 | 1 |
| Jun 03, 2016: New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA (Buprenorphine) Buccal Film For Chronic Pain | 329 | 1 |
| May 19, 2016: Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY | 330 | 1 |
| May 11, 2016: Pain Therapeutics To Present New Remoxy Data At American Pain Society Meeting | 331 | 1 |
| Apr 29, 2016: Voyager Therapeutics Announces Update on VY-NAV01 at R&D Day | 331 | 1 |
| Apr 12, 2016: DURECT Announces FDA Acceptance of REMOXY NDA, PDUFA Date of September 25, 2016 | 332 | 1 |
| Mar 29, 2016: DURECT Announces Resubmission of REMOXY New Drug Application to the U.S. Food and Drug Administration | 332 | 1 |
| Mar 08, 2016: Relmada Therapeutics to Present at the 28th Annual ROTH Conference | 332 | 1 |
| Mar 04, 2016: BioDelivery Sciences to provide an update on BELBUCA (buprenorphine) at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference | 333 | 1 |
| Appendix | 334 | 2 |
| Methodology | 334 | 1 |
| Coverage | 334 | 1 |
| Secondary Research | 334 | 1 |
| Primary Research | 334 | 1 |
| Expert Panel Validation | 334 | 1 |
| Contact Us | 334 | 1 |